OMTX705

DRUG4 trials

Sponsors

Oncomatryx Biopharma S.L.

Conditions

Advanced Solid TumorAdvanced/Metastatic Non-squamous Non-Small Cell Lung CancerAdvanced/metastatic colorectal cancerPancreatic Adenocarcinoma Metastatic

Phase 1

Efficacy and Safety Study of OMTX705, Monotherapy and Anti-PD-1-combined, in Subjects With Advanced Solid Tumors.

RecruitingNCT05547321

Oncomatryx Biopharma S.L.Advanced Solid Tumor

Start: 2022-10-20End: 2027-12-31Target: 150Updated: 2025-11-25

Phase 1b/2 dose-escalation trial of OMTX705, an anti-fibroblast activation protein antibody-drug conjugate, in combination with regorafenib and tislelizumab in patients with advanced/metastatic colorectal cancer

RecruitingCTIS2025-520743-33-00

Oncomatryx Biopharma S.L.Advanced/metastatic colorectal cancer

Start: 2025-07-23Target: 69Updated: 2025-07-21

Phase 1b/2 Trial of OMTX705, an Anti-Fibroblast Activation Protein Antibody-Drug Conjugate, in Combination with Carboplatin, Pemetrexed and Tislelizumab in Patients with Advanced/Metastatic Non-squamous Non-Small Cell Lung Cancer

Not yet recruitingCTIS2025-521989-95-00

Oncomatryx Biopharma S.L.Advanced/Metastatic Non-squamous Non-Small Cell Lung Cancer

Target: 88Updated: 2025-12-12

Clinical Trial of OMTX705 in Combination With Gemcitabine/Nab-Paclitaxel and Tislelizumab in Patients With Advanced/Metastatic Pancreatic Adenocarcinoma

RecruitingNCT07377045

Oncomatryx Biopharma S.L.Pancreatic Adenocarcinoma Metastatic

Start: 2025-10-28End: 2029-03-01Target: 69Updated: 2026-01-29

Related Papers

First-in-human phase 1 dose escalation trial of OMTX705, a novel anti-fibroblast activation protein (FAP) antibody drug conjugate (ADC), in monotherapy and in combination with pembrolizumab in patients with solid tumors.

Journal of Clinical Oncology2025-05-284 citations